



## Bio-Nano Interfaces: From Biosensors to Nanomedicines

Guest Editors:

**Dr. Filomena A. Carvalho**

Instituto de Medicina Molecular,  
Faculdade de Medicina,  
Universidade de Lisboa, Lisbon,  
Portugal

**Prof. Dr. Nuno C. Santos**

Instituto de Medicina Molecular,  
Faculdade de Medicina,  
Universidade de Lisboa, 1649-028  
Lisbon, Portugal

Deadline for manuscript  
submissions:

**closed (30 September 2023)**

### Message from the Guest Editors

Dear Colleagues,

New biomarkers associated with different diseases are urgently needed to improve patient survival. Biomolecules allow for determining the optimal treatment, establishing a clinical diagnosis and enabling clinical prognosis in neurological, cardiovascular and infectious diseases, as well as in cancer. Highly promising strategies to detect specific biomarkers often rely on the design of specific biosensors; these techniques are expected to improve sensitivity, selectivity, reproducibility and response time. Clinical and non-clinical biosensors can be categorized into different types of detection. They use enzymes, cells, antibodies, DNA, nanoparticles or the pathogenic agent itself, such as bacteria or viruses, to enact their effects. This paves the way for a plethora of different applications, including the use of biosensors in diagnostic kits for SARS-CoV-2 detection. This Special Issue will explore the intersection between nanosciences, biology and medicine, presenting various research approaches to biosensors' application in clinical diagnosis and care, including their fabrication, accompanying challenges and future trends in their development.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)